Qrons Inc. (QRON)
USD 0.18
(0.0%)
USD 0.18
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -40.08 Thousand USD | 76.86% |
| 2022 | -629.62 Thousand USD | 21.49% |
| 2021 | -801.95 Thousand USD | -44.82% |
| 2020 | -553.74 Thousand USD | 63.48% |
| 2019 | -1.51 Million USD | 61.17% |
| 2018 | - USD | -178.3% |
| 2017 | - USD | -748.49% |
| 2016 | - USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -86.37 Thousand USD | 100.0% |
| 2024 Q2 | -79.25 Thousand USD | 0.0% |
| 2023 FY | - USD | 76.86% |
| 2023 Q3 | -439.55 Thousand USD | -1777.0% |
| 2023 Q1 | -36.94 Thousand USD | 92.79% |
| 2023 Q2 | -23.41 Thousand USD | 36.61% |
| 2023 Q4 | -143.76 Thousand USD | 67.29% |
| 2022 Q2 | -31.06 Thousand USD | 51.12% |
| 2022 Q4 | -512.55 Thousand USD | -2183.01% |
| 2022 FY | - USD | 21.49% |
| 2022 Q1 | -63.55 Thousand USD | 90.8% |
| 2022 Q3 | -22.45 Thousand USD | 27.73% |
| 2021 Q1 | -38.36 Thousand USD | 85.12% |
| 2021 FY | - USD | -44.82% |
| 2021 Q4 | -690.48 Thousand USD | -2178.3% |
| 2021 Q2 | -42.79 Thousand USD | -11.56% |
| 2021 Q3 | -30.3 Thousand USD | 29.19% |
| 2020 FY | - USD | 63.48% |
| 2020 Q1 | -218.93 Thousand USD | 63.14% |
| 2020 Q2 | -13.58 Thousand USD | 93.79% |
| 2020 Q3 | -63.42 Thousand USD | -366.76% |
| 2020 Q4 | -257.78 Thousand USD | -306.42% |
| 2019 Q3 | -459.74 Thousand USD | -130.84% |
| 2019 Q2 | -199.15 Thousand USD | 24.42% |
| 2019 Q1 | -263.51 Thousand USD | 88.02% |
| 2019 FY | - USD | 61.17% |
| 2019 Q4 | -594.01 Thousand USD | -29.21% |
| 2018 Q3 | -534.31 Thousand USD | 21.8% |
| 2018 FY | - USD | -178.3% |
| 2018 Q2 | -683.25 Thousand USD | -39.83% |
| 2018 Q1 | -488.62 Thousand USD | 63.38% |
| 2018 Q4 | -2.19 Million USD | -311.51% |
| 2017 Q2 | -19.36 Thousand USD | -1691.77% |
| 2017 Q1 | -1081.00 USD | 99.32% |
| 2017 FY | - USD | -748.49% |
| 2017 Q4 | -1.33 Million USD | -2667.53% |
| 2017 Q3 | -48.21 Thousand USD | -148.95% |
| 2016 Q3 | -5480.00 USD | 0.0% |
| 2016 Q4 | -159.89 Thousand USD | -2817.7% |
| 2016 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 99.944% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 99.324% |
| SQZ Biotechnologies Company | -64.14 Million USD | 99.938% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 99.769% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 100.043% |
| Mesoblast Limited | -62.38 Million USD | 99.936% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 97.391% |
| Genus plc | 73.7 Million USD | 100.054% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 99.394% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 98.87% |
| Marizyme, Inc. | -34.28 Million USD | 99.883% |
| ContraFect Corporation | -64.99 Million USD | 99.938% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 99.543% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 99.114% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 97.141% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 98.484% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | 98.275% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | 92.263% |
| Accustem Sciences Inc. | -3.74 Million USD | 98.93% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 99.917% |
| EV Biologics, Inc. | -1.26 Million USD | 96.837% |
| Q BioMed Inc. | -617.62 Thousand USD | 93.51% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 101.122% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 93.662% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | 98.246% |
| Biomind Labs Inc. | -1.03 Million USD | 96.126% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 100.406% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 99.44% |
| Skye Bioscience, Inc. | -13.54 Million USD | 99.704% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | 97.305% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -60.324% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 98.968% |
| IMV Inc. | -35.52 Million USD | 99.887% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 99.747% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 98.398% |
| GB Sciences, Inc. | -1.41 Million USD | 97.177% |
| Alpha Cognition Inc. | -9.7 Million USD | 99.587% |
| HST Global, Inc. | -5303.00 USD | -655.817% |
| CSL Limited | 4.78 Billion USD | 100.001% |
| Halberd Corporation | -74.27 Thousand USD | 46.04% |
| Enzolytics Inc. | -2.12 Million USD | 98.111% |
| Resverlogix Corp. | -11.74 Million USD | 99.659% |
| Affymax, Inc. | -14.29 Million USD | 99.72% |
| SYBLEU INC | -141.57 Thousand USD | 71.688% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 98.691% |
| argenx SE | -216.02 Million USD | 99.981% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 99.928% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 103.293% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | 97.326% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 110.58% |
| AVAX Technologies, Inc. | -6.11 Million USD | 99.344% |
| Zenith Capital Corp. | -8.6 Million USD | 99.534% |
| Genscript Biotech Corporation | -248.71 Million USD | 99.984% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -130.073% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 98.362% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | 77.23% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 99.899% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 98.614% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | 96.169% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 696.089% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | 97.71% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | 97.913% |
| BioStem Technologies, Inc. | -7.55 Million USD | 99.469% |
| ONE Bio Corp. | 13.61 Million USD | 100.294% |
| Reve Technologies, Inc. | -181.08 Thousand USD | 77.867% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | 98.051% |
| Agentix Corp. | -1.37 Million USD | 97.078% |
| LadRx Corporation | 412.28 Thousand USD | 109.722% |
| Cell Source, Inc. | -4.27 Million USD | 99.062% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | 89.085% |
| Regen BioPharma, Inc. | 1.46 Million USD | 102.734% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | 95.722% |
| NovAccess Global Inc. | -1.03 Million USD | 96.127% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 100.453% |
| Itoco Inc. | -1.86 Million USD | 97.855% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | 89.442% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 96.409% |
| Kadimastem Ltd | -2.62 Million USD | 98.473% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | 83.24% |
| CytoDyn Inc. | -18.02 Million USD | 99.778% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | 49.283% |
| Mobile Lads Corp. | -2.24 Million USD | 98.212% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -227.754% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | 91.747% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 107.599% |
| Rebus Holdings, Inc. | -951 Thousand USD | 95.785% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | 96.226% |
| International Stem Cell Corporation | 202 Thousand USD | 119.842% |
| Bioxytran, Inc. | -3.82 Million USD | 98.951% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | 23.858% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | 98.372% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 99.888% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | 10.931% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 98.536% |
| Neutra Corp. | -181.24 Thousand USD | 77.886% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 99.801% |
| PureTech Health plc | -11.62 Million USD | 99.655% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 99.801% |
| IXICO plc | -707 Thousand USD | 94.331% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 99.478% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 99.917% |
| CSL Limited | 4.73 Billion USD | 100.001% |
| Cellectis S.A. | -92.63 Million USD | 99.957% |